| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
・VASH1 expression inhibited tumor vascularization and growth, not only in high VEGF-producing ovarian cancer cells, but also in high PDGF-producing ovarian cancer cells, reduced their peritoneal dissemination and ascites, and prolonged host survival. These results suggest that VASH1 is an effective treatment for ovarian cancer.
・NK4 can inhibit ovarian cancer growth in vivo by inhibition of IDO expression via the c-Met-PI3K-AKT signaling pathway. These results suggest that NK4 represents a potentially useful immunotherapeueutic anticancer agent for ovarian cancer.
|
